$97,773.14 research Payment -- Pfizer Inc to Dr. Matthew Walker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Pfizer Inc made a $97.8K research payment to Matthew Walker, a Cardiology specialist in City, VA. The payment was associated with Rybelsus. Pfizer Inc. paid Matthew Walker, a cardiologist, $97,773.14 for research related to Rybelsus. The payment was made on February 8, 2025, indicating a recent research collaboration. This payment falls under the 'research' category, suggesting support for clinical trials or studies.

Patient Guidance: What This Payment Means for You

This payment is for research related to a medication and does not represent a direct payment for your personal medical care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Research payments to cardiologists can vary widely depending on the scope and duration of the study, but this amount is within a moderate range for significant research initiatives.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Sunshine Act, which requires disclosure of payments made by drug and device manufacturers to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

• pfizer-inc
• matthew-walker
• rybelsus
• cardiology
• research-payment
• cms-open-payments

Understanding research Payments

Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.

Frequently Asked Questions About This Payment

What was this $97.8K payment for?

This was a research payment of $97.8K from Pfizer Inc to Matthew Walker, categorized as "Research". It was associated with Rybelsus. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Matthew Walker accept pharmaceutical money?

Yes, Matthew Walker received this $97.8K payment from Pfizer Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Matthew Walker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this research payment?

A research payment of $97.8K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Cardiology?

To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Matthew Walker's relationship with Pfizer Inc?

The payment amount is substantial, suggesting a significant research project. This $97.8K research payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Cardiology?

The specific drug, Rybelsus, is identified, allowing for focused analysis of its research funding.

What should patients do after learning about this payment?

This payment is for research related to a medication and does not represent a direct payment for your personal medical care.

What else should I know about this research payment?

The payment date is in the future, implying ongoing or planned research activities.

Related Reports

• View Dr. Matthew Walker's full payment report
• Pfizer Inc full spending report
• Browse all Cardiology payments
• Browse all payments in Virginia
• Search for other payments